Medical Treatments for Prostate CancerThere are many different medical treatments for prostate cancer that involve the clinical care of a healthcare professional. These treatments include expectant therapy, surgery, radiation therapy, hormone therapy, and chemotherapy. Expectant therapy is to carefully observe and monitor the prostate cancer. Because prostate cancer cells often spread very slowly, many older men who have the disease may not need more extensive treatment. However, expectant therapy usually includes routine physician examinations, including digital rectal exams and PSA tests. The different types of surgery for prostate cancer are radical prostatectomy - an open-surgery procedure in which the entire prostate gland and surrounding tissue are removed. Transurethral resection of the prostate (TURP) - surgery to remove part of the prostate gland that surrounds the urethra. Cryosurgery - this procedure involves killing the cancer cells by freezing them with a small metal tool placed in the tumor. Side effects of prostate cancer surgery include incontinence and impotence. Incontinence is the inability to control urine and may result in dribbling of urine, especially immediately after surgery. Normal control usually returns within weeks or months after surgery. Impotence is the inability to achieve an erection. For a month, or so, after surgery, most men are not able to get an erection. Eventually, approximately 40 to 60 percent of men will be able to get an erection sufficient for sexual intercourse, but without ejaculation of semen, since removal of the prostate gland prevents that process.Radiation therapy uses high energy rays to kill or shrink cancer cells, and to decrease their ability to divide. Radiation is often used to treat prostate cancer that is still confined to the prostate gland, or has spread only to nearby tissue. If the disease is advanced, radiation may be used to reduce the size of the tumor and to provide relief from symptoms. Possible side effects of radiation for prostate cancer may include diarrhea, with or without blood in the stool, and colitis, problems associated with urination, a degree of impotence (inability to get an erection), which may occur within two years of radiation therapy. The goal of hormone therapy is to lower the level of male hormones in the body, particularly testosterone. Hormone therapy does not cure the cancer, and is often used to treat persons whose cancer has spread or recurred after treatment. Produced mainly in the testicles, testosterone causes prostate cancer cells to grow. Thus, reduced testosterone levels can make the prostate cancer shrink and become less active. Most studies show that hormone therapy works better if it is started early. Chemotherapy is the use of powerful, anti-cancer medications to kill cancer cells.. Hospitalization may be needed to monitor treatment and chemotherapy's side effects. Common side effects of chemotherapy include: nausea and vomiting, hair loss, anemia, reduced ability of blood to clot, mouth sores, increased likelihood of developing infections, fatigue. Most side effects disappear once treatment is stopped. |
| androgen independent prostate carcinoma |
|
Combination Chemotherapy following Adrenal Suppression in Androgen Table 1. Recent chemotherapeutic trials in androgen-independent prostate cancer Fournier G: Treatment of hormone-refractory prostate carcinoma. Signal transduction pathways in androgen-dependent and Androgen-independent prostate cancer (AIPC) tends to progress and MC 2001 Type I collagen-mediated proliferation of PC3 prostate carcinoma cell line: Therapy Tolerance in Selected Patients With Androgen-Independent Indeed, many patients with androgen-independent prostate cancer and bone metastases have in the treatment of androgen-independent prostate carcinoma. News - Thalidomide Combination Shows Activity in Androgen Xanthogranulomatous Prostatitis: A Mimic of Carcinoma of Prostate The study has enrolled 30 patients with androgen-independent prostate cancer Id-1 expression induces androgen-independent prostate cancer cell B-induced PSA expression and its role in androgen-independent prostate cancer cell . of an androgen-independent transplantable carcinoma of the prostate. Transcription-targeted gene therapy for androgen-independent The most dramatic increase was seen in the androgen-independent prostate cancer .. prostate carcinoma cells enhances prodrug and radiation sensitivity. Phase I Trial of Docetaxel With Estramustine in Androgen This combination is active in men with androgen-independent prostate cancer. . Case 21-2004 - A 63-Year-Old Man with Metastatic Prostate Carcinoma Lycopene inhibits the growth of human androgen-independent These results suggest that lycopene may specifically inhibit the growth of androgen-independent prostate cancers. apoptosis; carcinoma; disease models; Lycopene Inhibits the Growth of Human Androgen-Independent We studied the inhibitory effects of lycopene on the proliferation of 3 different human prostate carcinoma cell lines, including androgen-independent NEJM -- Mutation of the Androgen-Receptor Gene in Metastatic Conclusions Most metastatic androgen-independent prostate cancers express .. Gene 1 Modulates Androgen Receptor Signaling in Prostate Carcinoma Cells. P2-purinergic receptor agonists inhibit the growth of androgen These data demonstrate that human androgen-independent prostate carcinoma cells express functional P2-purinergic receptors linked to phospholipase C, Vinorelbine, doxorubicin, and prednisone in androgen-independent for the treatment of androgen-independent prostate cancer (AIPC) is essential. endocrine-refractory carcinoma of the prostate. J Clin Oncol. Interleukin-4 Receptor-targeted Cytotoxin Therapy of Androgen Interleukin-4 Receptor-targeted Cytotoxin Therapy of Androgen-dependent and -independent Prostate Carcinoma in Xenograft Models 1 Management of Androgen-Independent Prostate Cancer Sandow J, von Rechenberg W, Engelbart K. Pharmacological studies on androgen suppression in therapy of prostate carcinoma. Am J Clin Oncol. Myc confers androgen-independent prostate cancer cell growth Thus, finding an effective treatment for androgen-independent prostate cancer (AIPC) and tumor suppressor activity of Bin1 in prostate carcinoma. Multidrug resistance in androgen-independent growing rat prostate in the androgen-independent prostate carcinoma cells is. likely to be mediated by a combination of different re-. sistance mechanisms, because it cannot be Urology : Imatinib mesylate and zoledronic acid in androgen Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer*1 9, 10 and 11 and inhibit prostate carcinoma cell invasion in vitro. Progression after docetaxel-based chemotherapy in androgen 4 Tu SM, Millikan RE, Mengistu B et al. Bone-targeted therapy for advanced. androgen-independent carcinoma of the. prostate: a randomised phase II trial. |
| androgen independent prostate carcinoma |
|
bike saddle prostate benign prostate hypertrophy treatment cancer nutritional prostate supplement bolesti prostate |